Navigation Links
Mutations in the BRAF gene predict sensitivity to a novel class of cancer drugs

A team of researchers led by scientists at Memorial Sloan-Kettering Cancer Center have discovered that a new class of drugs -- now in early stage clinical trials -- work best in patients with mutations in the BRAF gene. BRAF is a protein that plays a central role in the growth and survival of cancer cells and is mutated in the majority of patients with melanoma and in a minority of patients with colon, breast, and lung cancers. The findings, available in an advance online publication of Nature, represent a potential targeted therapy tailored for patients whose tumors contain this mutation.

The researchers found that drugs that inhibit a protein called MEK selectively inhibited the growth of cancer cells lines and tumors that have a mutated BRAF gene. One of these drugs, PD0325901 (developed by Pfizer Research and Development), is now being tested in clinical trials of patients with melanoma, colon, breast, and lung cancers. In addition, by re-analyzing the data on more than 42,000 compounds tested by the National Cancer Institute against a panel of 60 cancer cell lines, the investigators were able to identify a small number of other compounds that also selectively inhibit tumors that have the BRAF mutation. While the mechanism of action of some of these compounds has yet to be determined, several of the most effective compounds were also inhibitors of the MEK protein.

"We find that all tumors with the BRAF mutation and some with the RAS mutation are sensitive to drugs that inhibit MEK," explained Dr. Neal Rosen, Professor of Medicine and a member and laboratory head in the Molecular Pharmacology and Chemistry Program at Memorial Sloan-Kettering and the study's senior author. "Translating these findings into a strategy for treating patients whose tumors are dependent upon this specific genetic change is the next step, and such clinical trials are now ongoing."

"The BRAF mutation was first identified by a consortium of investigators searching fo r proteins that are frequently mutated in human cancer," said Dr. David Solit, the study's first author and a medical oncologist at Memorial Sloan-Kettering who is also a member of Dr. Rosen's laboratory. This project, an outgrowth of the Human Genome Project, called the Cancer Genome Project, has the goal of identifying the causative mutations that cause human cancers.

"This represents what we believe will be the first of a series of new drugs that specifically target cancer cells that contain mutations identified by the Cancer Genome sequencing effort," said Dr. Solit. "The hope is that these new targeted therapies will be more effective and less toxic than traditional chemotherapies."

The study's other researchers were Christine A. Pratilas, Ayana Sawai, Andrea Basso, Qing Ye, Jose M. Lobo, and Yuhong She, all of Memorial Sloan-Kettering; Drs. Levi A.Galloway, Gad Getz, Todd R. Golub, and William R. Sellers of Dana-Farber Cancer Institute and Broad Institute of MIT and Harvard; Dr. Iman Osman of New York University Medical College; and Dr. Judith Sebolt-Leopold of Pfizer Global Research and Development.


'"/>

Source:Memorial Sloan-Kettering Cancer Center


Related biology news :

1. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
2. Biomarkers isolated from saliva successfully predict oral and breast cancer
3. Multiple-drug resistant gene expression pattern predicts treatment outcome for pediatric leukemia
4. Ocean climate predicts elk population in Canadian Rockies
5. Understanding biases in epidemic models important when making public health predictions
6. Identification of specific genes predicts which patients will respond to Hepatitis C treatment
7. UNC computer, marine scientists collaborate to predict flow of toxic waters from Katrina
8. Rensselaer researchers develop approach that predicts protein separation behavior
9. Researchers predict infinite genomes
10. Modification of program enables prediction of gene transcription
11. Computers close in on protein structure prediction
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/22/2016)... India , March 22, 2016 /PRNewswire/ ... market research report "Electronic Sensors Market for Consumer ... Proximity, & Others), Application (Communication & IT, ... Geography - Global Forecast to 2022", published ... industry is expected to reach USD 26.76 ...
(Date:3/15/2016)... , March 15, 2016 ... report published by Transparency Market Research "Digital Door Lock Systems ... Forecast 2015 - 2023," the global digital door lock systems ... Mn in 2014 and is forecast to grow at a ... of micro, small and medium enterprises (MSMEs) across the world ...
(Date:3/11/2016)... , March 11, 2016 ... market research report "Image Recognition Market by Technology (Pattern ... and Advertising), by Deployment Type (On-Premises and Cloud), by ... 2022", published by MarketsandMarkets, the global market is expected ... USD 29.98 Billion by 2020, at a CAGR of ...
Breaking Biology News(10 mins):
(Date:4/26/2016)... (PRWEB) , ... April 26, 2016 , ... ... laser lithography systems, announces the latest technology innovation for its Volume Pattern Generator ... tomorrow’s demand for production of advanced photomasks as well as a solution for ...
(Date:4/26/2016)... MA (PRWEB) , ... April 26, 2016 , ... This ... Town Scottsdale and will offer attendees an opportunity to get the lowdown on female ... , Over cocktails and appetizers, Dr. Jesse Hade, of Boston IVF - The Arizona ...
(Date:4/26/2016)... ... 26, 2016 , ... Seattle based non-profit, The Institute for ... Corporation. The grant will be used to further the scientific research goals of ... http://www.ivsci.org , In accounting the grant to the IVS, Mr. Glenn ...
(Date:4/26/2016)... , ... April 26, 2016 , ... uBiome, the leading ... new position on the company’s Advisory Board. Prior to co-founding Plum in 2007, Neil ... Senior Designer at IDEO. , A renowned, innovative designer of ideas, products, and brands, ...
Breaking Biology Technology: